Nabriva Commences Exclusive Distribution of SIVEXTRO® (tedizolid phosphate) in the U.S.
April 15, 2021 12:12 ET
|
Nabriva Therapeutics US, Inc
- SIVEXTRO now available under Nabriva’s National Drug Code - 100% of SIVEXTRO’s net product sales to be recorded by Nabriva DUBLIN, Ireland and FORT WASHINGTON, Pa., April 15, 2021 (GLOBE...
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2021 16:01 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland, April 02, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
Nabriva Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
April 01, 2021 08:00 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland and KING OF PRUSSIA, Pa., April 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...
Nabriva Publishes Clinical Data Analysis Highlighting Benefits of Outpatient Management of Community Acquired Bacterial Pneumonia (CABP) with Oral XENLETA® (lefamulin)
March 16, 2021 08:00 ET
|
Nabriva Therapeutics US, Inc
-Post Hoc analysis published in The Journal of Emergency Medicine demonstrates patients with moderate to severe CABP can be managed effectively as outpatients with a 5-day, monotherapy regimen of oral...
Nabriva Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Updates
March 11, 2021 16:07 ET
|
Nabriva Therapeutics US, Inc
-Relaunched XENLETA® (lefamulin) and SIVEXTRO® (tedizolid phosphate) in the community with 60 sales representatives- -Nabriva plans to initiate a Phase 1 clinical trial of XENLETA in patients with...
Nabriva Therapeutics to Report 2020 Financial Results and Recent Corporate Highlights on March 11, 2021
March 03, 2021 16:05 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland, March 03, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
March 01, 2021 08:00 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland and KING OF PRUSSIA, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and...
Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer
February 26, 2021 08:00 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...
Study Demonstrates Macrolide-Resistance in S. pneumoniae in the United States Exceeds 25 Percent Threshold Set in Current Community-Acquired Bacterial Pneumonia (CABP) Treatment Guidelines
February 23, 2021 07:00 ET
|
Nabriva Therapeutics US, Inc
Contemporary data demonstrate macrolide resistance in S. pneumoniae is 39.5 percent overall and greater than 25 percent in most regions of the country Macrolide resistance shown to be significantly...
Nabriva Therapeutics Announces Retirement of its Chief Financial Officer
February 01, 2021 16:30 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...